View More Recent Stories
-
William Blair Reiterates Outperform Rating on Rocket Pharmaceuticals (RCKT)
-
BMO Capital on Rocket Pharmaceuticals (RCKT): 'we expect today's announcement...to significantly pressure RCKT'
-
Jefferies on Rocket Pharmaceuticals (RCKT): 'We expect significant stock weakness'
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $32 at BofA Securities
-
Morgan Stanley on Rocket Pharmaceuticals (RCKT): 'we expect RCKT shares to be under significant pressure today'
-
JPMorgan on Rocket Pharmaceuticals (RCKT): 'we wouldn’t be surprised by shares continuing to be under pressure'
-
Rocket Pharmaceuticals (RCKT) Provides Update on Phase 2 Trial of RP-A501
-
Rocket Pharmaceuticals Price Target Raised to $30.00 at Cantor Fitzgerald (RCKT)
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $18 at Evercore ISI
-
Rocket Pharmaceuticals (RCKT) Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
-
Rocket Pharmaceuticals (RCKT) Tops Q1 EPS by 3c
-
BMO Capital: 'Rocket Pharmaceuticals (RCKT) Poised for an Asymmetric Rebound in 2Q25+'
-
Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Rocket Pharmaceuticals (RCKT)
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
BMO Capital Starts Rocket Pharmaceuticals (RCKT) at Outperform
-
Rocket Pharmaceuticals (RCKT) PT Raised to $52 at Scotiabank
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $36 at Canaccord Genuity
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $50 at Cantor Fitzgerald
-
Rocket Pharmaceuticals (RCKT) Tops Q4 EPS by 10c
-
Jefferies Starts Rocket Pharmaceuticals (RCKT) at Buy
-
Rocket Pharmaceuticals (RCKT) Prices Upsized 13.2M Share Offering at $12.50/sh
-
After-hours movers: GM, Stitch Fix, Dave & Buster's, GME and more
-
Rocket Pharmaceuticals (RCKT) Announces Proposed Public Offering of Common Stock
-
Canaccord Genuity Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT)
-
Rocket Pharmaceuticals (RCKT) Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data
-
Rocket Pharmaceuticals (RCKT) PT Raised to $39 at Canaccord Genuity
-
Rocket Pharmaceuticals (RCKT) Tops Q3 EPS by 4c
-
Canaccord Genuity Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT)
-
Morgan Stanley on Rocket Pharmaceuticals (RCKT): 'we are encouraged by rapid enrollment'
-
Rocket Pharmaceuticals (RCKT) Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
-
Rocket Pharmaceuticals (RCKT) Appoints Mikael Dolsten to its Board
-
Rocket Pharmaceuticals (RCKT) Files Mixed Shelf
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $38 at Canaccord Genuity
-
Rocket Pharmaceuticals (RCKT) Misses Q2 EPS by 2c
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $40 at Canaccord Genuity
-
Rocket Pharmaceuticals (RCKT) to Resume Trading at 8 a.m.
-
Rocket Pharmaceuticals (RCKT) Provides Regulatory Update on KRESLADI
-
Rocket Pharmaceuticals (RCKT) Halted, News Pending

